CRISPR-inhibition screen for lncRNAs linked to melanoma growth and metastasis
Stavroula PetrouliaiD, Kathryn HockemeyeriD, Shashank TiwariiD, Pietro BericoiD, Sama ShamlooiD, Seyedeh Elnaz BanijamaliiD, Eleazar Vega‐Saenz de MieraiD, Yixiao GongiD, Palaniraja ThandapaniiD, Eric WangiD, Michael SchulziD, Aristotelis TsirigosiD, Iman OsmaniD, Iannis AifantisiD, Jochen ImigiD
Abstract
Melanoma being one of the most common and deadliest skin cancers, has been rising since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays the standard-of-care of advanced melanoma is resection followed by immune checkpoint inhibition based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistances. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long non-coding RNAs (lncRNAs) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistances, however systematic screens to uncover novel functional lncRNAs are scarce. Here, we profile differentially expressed lncRNAs in patient derived short-term metastatic cultures and BRAF-MEK-inhibition resistant cells. We conduct a focused growth-related CRISPR-inhibition screen of overexpressed lncRNAs, validate and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance on melanoma. SignificancePreviously considered as transcriptional noise, lncRNAs have emerged as novel players in regulating many cellular aspects in health and disease including melanoma. However, the number and as well as the extent of functional significance of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR-inhibition growths screens lowering the experimental effort. We also provide a larger resource of differentially expressed lncRNAs with potential implications in melanoma growth and invasion. Our results broaden the characterized of lncRNAs as potential targets for future therapeutic applications.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 1.25
- Field percentile
- top 22%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo CRISPRi screen identified lncRNA portfolio crucial for cutaneous squamous cell carcinoma tumor growth
Gyuhyeon Kim, Zurab Siprashvili, … Luca Ducoli·Journal of Investigative DermatologyPeer-reviewed·May 27, 2025
- CRISPRi Screen Identifies a Novel Growth Suppressor lncRNA, INSTAR, in Human Monocytes
Christy Montano, Eric Malekos, … Susan B Carpenter·bioRxiv·Oct 30, 2025
- Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities
Roberta Esposito, Taisia Polidori, … Rory Johnson·Cell GenomicsPeer-reviewed·Aug 22, 2022
- In vivo selection reveals long non-coding RNAs implicated in colon to liver metastasis
A. Soroosh, D. M. Padua, … C. R. Rankin·bioRxiv·May 23, 2022
- Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation
Shiyang Liu, Nathan Harmston, … Enrico G. Petretto·Genome MedicinePeer-reviewed·Oct 22, 2020
- The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor
E. A. Coe, J. Y. Tan, … K. W. Vance·bioRxiv·Mar 27, 2019